Cerebral venous thrombosis after intravenous immunoglobulin therapy in immune thrombocytopenic purpura

Shiji, PV; Radhakrishnan, Chandni

doi:10.4103/ijccm.ijccm_308_17

Cited by 6 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…on the cerebral venous thrombosis after intravenous immunoglobulin (IVIG) therapy in a patient with immune thrombocytopenic purpura. [ 1 ] The case report generally supports the trend of increasing reports of IVIG-associated thrombotic events in all age groups, including pediatric age group. [ 2 ] It is obvious that the tolerance of IG is usually good, but adverse events, including some serious ones, have been reported and may differ among different IG preparations.…”

supporting

confidence: 78%

Cerebral Venous Thrombosis after Intravenous Immunoglobulin Therapy in Immune Thrombocytopenic Purpura

Al‐Mendalawi

2018

Indian Journal of Critical Care Medicine

View full text Add to dashboard Cite

supporting

confidence: 78%

Cerebral Venous Thrombosis after Intravenous Immunoglobulin Therapy in Immune Thrombocytopenic Purpura

Al‐Mendalawi

2018

Indian Journal of Critical Care Medicine

View full text Add to dashboard Cite

“…ITP increases the risk of both arterial and venous thrombosis, including CVT, because of the chronic inflammatory state associated with the disease, even with thrombocytopenia. ITP may be a manifestation of an evolving tissue disorder also associated with an increased risk of thrombosis [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Cerebral Venous Thrombosis and Its Clinical Diversity

Ennis

Domingues

Marques

et al. 2021

Cureus

View full text Add to dashboard Cite

Cerebral venous thrombosis (CVT) is a serious medical condition which is difficult to diagnose because of its wide range of clinical presentations. The symptoms can vary from an isolated headache to coma. Here, we present the case of a 76-year-old female patient with a history of immune thrombocytopenic purpura, arterial hypertension, and pulmonary embolism. The diagnosis of CVT was challenging because the initial form of disease presentation mimicked a transient ischemic attack (transient aphasia and right hemiparesis). Therapeutical decisions were also a challenge because, at the time of the diagnosis, the patient was suffering from severe thrombocytopenia (29 × 10 9 /L), which had to be taken into account. After multidisciplinary discussions, therapeutic subcutaneous enoxaparin was started, resulting in a progressive and significant neurological recovery. In presenting this case, our primary goal is to point out that CVT can be difficult to diagnose because of its wide range of clinical presentations. Headache (a symptom that was never present in this case) is the most frequent complaint, occurring in 90% of cases. Following diagnosis, an etiological study is required.

show abstract